INPP5A was recently identified as a drug target in uveal melanoma (UVM) with activating mutations in the guanosine nucleotide-binding protein Q gene (GNAQ) or its paralog guanosine nucleotide-binding protein alpha-11 gene (GNA11), which occur in approximately 90% of these cancers.31 Here, GNAQ is linked to cancer.